Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and mechanistic studies with no new human data
PubMed 31775341 · doi:10.3390/ijms20235920
What was done
This narrative review summarizes literature on the role of mitochondrial dysfunction and oxidative stress in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), focusing on the mechanisms of Nrf2 activation by glucoraphanin and sulforaphane.
What was found
The abstract reports no quantitative values or statistical metrics. It describes qualitative mechanistic findings: pharmacological Nrf2 activation ameliorates obesity-associated insulin resistance and NAFLD in mouse models, and glucoraphanin/sulforaphane act as potent Nrf2 inducers that may protect mitochondrial function and suppress NASH progression.
Why it matters
It outlines how dietary Nrf2 inducers could theoretically target mitochondrial dysfunction and oxidative stress in fatty liver pathogenesis.
Limits
As a narrative review, it reports no new empirical data. Evidence discussed in the abstract is limited to mechanistic concepts and mouse models, without human clinical trial data or quantitative effect sizes.
Cited by
- supports Sulforaphane is the most potent natural activator of Nrf2 discovered to date.